Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection

Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection

The effects of casirivimab and imdevimab (C/I) on the innate immune response against SARS-CoV-2 infection remain unclear. We evaluated the effect of C/I on type I interferon (IFN-I) and cytokines in patients with SARS-CoV-2 infection. This prospective observational study recruited consecutive patien...

Full description

Bibliographic Details
Main Authors:	Kentaro Nagaoka, Hitoshi Kawasuji, Yusuke Takegoshi, Yushi Murai, Makito Kaneda, Akitoshi Ueno, Yuki Miyajima, Hideki Niimi, Yoshitomo Morinaga, Yoshihiro Yamamoto
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Series:	Viruses
Subjects:	COVID-19 type I interferon casirivimab imdevimab SARS-CoV-2 antibody-dependent enhancement
Online Access:	https://www.mdpi.com/1999-4915/14/7/1399

Similar Items

An initial experience with antibody cocktail CASIRIVIMAB and IMDEVIMAB in a center of excellence: A retrospective case series of 3 patients and literature review
by: P Amal Johnson, et al.
Published: (2021-01-01)

Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trial
by: Imam Adi Wicaksono, et al.
Published: (2023-12-01)

Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients
by: Sahar K. Hegazy, et al.
Published: (2023-06-01)

Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
by: Hegazy Sahar K., et al.
Published: (2023-08-01)

Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study
by: Marina S. Lebedkina, et al.
Published: (2023-08-01)

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
by: Flonza Isa, et al.
Published: (2022-09-01)

SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
by: Martin Heller, et al.
Published: (2023-04-01)

Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia
by: Alessandro Cozzi-Lepri, et al.
Published: (2024-03-01)

The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India
by: Aneesh Puthiyedath Joy, et al.
Published: (2022-03-01)

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
by: Andrea T. Hooper, et al.
Published: (2022-12-01)

Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
by: Gaetano Cicchitto, et al.
Published: (2022-03-01)

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
by: Valentina Mazzotta, et al.
Published: (2022-04-01)

Efficacy of Antibody Cocktail Drug in COVID-19 Positive Patients: A Retrospective Single-centered Study
by: Manoranjan Dash, et al.
Published: (2023-02-01)

Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis
by: Robert Hoepner, et al.
Published: (2022-03-01)

Successful treatment of persistent and severe SARS‐CoV‐2 infection in a high‐risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies
by: Fernanda Braga Seganfredo, et al.
Published: (2022-11-01)

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies
by: Juan C. Almagro, et al.
Published: (2022-08-01)

Antibody Cocktail in Moderate to Severe COVID-19 Infection: A Series of 10 Cases
by: Rohit Hanmanta Bhandari, et al.
Published: (2022-06-01)

First Case of COVID-19 Treated with Monoclonal Anti-Spike Antibodies in a Patient with Cystic Fibrosis in Romania
by: Iustina Violeta Stan, et al.
Published: (2022-01-01)

Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
by: Thomas J. Woltemate, et al.
Published: (2021-10-01)

Dominant CT Patterns and Immune Responses during the Early Infection Phases of Different SARS-CoV-2 Variants
by: Kentaro Nagaoka, et al.
Published: (2023-05-01)

High interleukin-6 levels induced by COVID-19 pneumonia correlate with increased circulating follicular helper T cell frequency and strong neutralization antibody response in the acute phase of Omicron breakthrough infection
by: Hitoshi Kawasuji, et al.
Published: (2024-04-01)

Neutralizing Antibody Therapeutics for COVID-19
by: Aeron C. Hurt, et al.
Published: (2021-04-01)

REGEN-COV and COVID-19, update on the drug profile and FDA status: A mini-review and bibliometric study
by: Saeid Mezail Mawazi, et al.
Published: (2022-03-01)

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
by: Fulvia Mazzaferri, et al.
Published: (2022-11-01)

Current Effective Therapeutics in Management of COVID-19
by: Kavya Atluri, et al.
Published: (2022-07-01)

Clinical Management of COVID-19: A Review of Pharmacological Treatment Options
by: Ashli M. Heustess, et al.
Published: (2021-05-01)

Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
by: Judith Pannier, et al.
Published: (2023-02-01)

Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy
by: Valentine Marie Ferré, et al.
Published: (2022-10-01)

High Incidence of Metastatic Infections in Panton-Valentine Leucocidin-Negative, Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia: An 11-Year Retrospective Study in Japan
by: Hitoshi Kawasuji, et al.
Published: (2023-10-01)

Effectiveness and Safety of Linezolid Versus Vancomycin, Teicoplanin, or Daptomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia: A Systematic Review and Meta-Analysis
by: Hitoshi Kawasuji, et al.
Published: (2023-04-01)

Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study
by: Yi Guo, et al.
Published: (2022-07-01)

Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients
by: Hitoshi Kawasuji, et al.
Published: (2021-04-01)

Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
by: Nicola Schiano Moriello, et al.
Published: (2023-02-01)

Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19.
by: Matteo Ruggeri, et al.
Published: (2023-01-01)

Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants
by: Yoshitomo Morinaga, et al.
Published: (2021-12-01)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Landray, M, et al.
Published: (2022)

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
by: Dateng Li, et al.
Published: (2023-08-01)

Predictive values of immune indicators on respiratory failure in the early phase of COVID-19 due to Delta and precedent variants
by: K. Nagaoka, et al.
Published: (2023-09-01)

Retraction of “Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients”
by: Hegazy Sahar K., et al.
Published: (2023-11-01)

Comparison of Monoclonal Antibody Cocktail (Casirivimab-Imdevimab) Treatment With Remdesivir and Favipiravir in Mild to Moderate COVID-19 Infection: A Retrospective Study
by: Rahul Rajaram Tambe, et al.
Published: (2023-02-01)